Trial Profile

An Observational, Prospective, Cohort Study to Evaluate Safety and Efficacy of Remsima in Patients With Ankylosing Spondylitis

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 11 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Infliximab (Primary) ; Adalimumab; Etanercept
Indications Ankylosing spondylitis
Focus Adverse reactions
Sponsors Celltrion

Most Recent Events

09 Dec 2024 Status changed from recruiting to discontinued. (Terminated)
12 Jul 2021 Results of a pooled analysis assessing long-term safety and effectiveness over 5 years from three observational studies: NCT02557295, NCT02326155 and NCT02557308 published in the Advances in Therapy
30 Apr 2020 Results of post marketing pooled analysis of six observational studies published in the BioDrugs

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com